News & Updates

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The long-term use of skeletal muscle relaxants (SMRs) for chronic pain is beneficial only in patients with painful spasms or cramps and neck pain but not in those with low back pain, fibromyalgia, and headaches, according to the results of a systematic review and meta-analysis.

In cutaneous squamous cell carcinoma patients treated with cemiplimab, prior radiotherapy is associated with improved progression-free survival (PFS). This finding suggests the potential for combination treatment with cemiplimab plus radiotherapy.

In the phase III LMS04 trial, induction therapy with doxorubicin and trabectedin, followed by trabectedin maintenance, improved survival in patients with metastatic or surgically unresectable soft-tissue or uterine leiomyosarcoma (LMS).

Sacubitril/valsartan appears to be safe and beneficial in the treatment of children with heart failure (HF) attributable to systemic left ventricular systolic dysfunction (LVSD), with the drug having comparable efficacy as enalapril, according to the 52-week data from the phase 2/3 PANORAMA-HF* trial.

A pharmacist-managed telemedicine during the COVID-19 pandemic has resulted in improvements in appointment adherence in the hospital-based (HB) clinic and increased reimbursement in the physician-based (PB) clinic, reports a study. Healthcare outcomes, however, show no significant change.